Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pacific Health Care Organization (PFHO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Pacific Health Care Organization (PFHO) over the last 17 years, with Q3 2025 value amounting to $2.2 million.

  • Pacific Health Care Organization's Cash & Equivalents fell 1442.41% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 1442.41%. This contributed to the annual value of $2.1 million for FY2024, which is 1698.1% down from last year.
  • Latest data reveals that Pacific Health Care Organization reported Cash & Equivalents of $2.2 million as of Q3 2025, which was down 1442.41% from $2.2 million recorded in Q2 2025.
  • Pacific Health Care Organization's Cash & Equivalents' 5-year high stood at $10.6 million during Q3 2022, with a 5-year trough of $2.0 million in Q1 2023.
  • Its 5-year average for Cash & Equivalents is $5.3 million, with a median of $2.5 million in 2024.
  • As far as peak fluctuations go, Pacific Health Care Organization's Cash & Equivalents crashed by 8107.11% in 2023, and later skyrocketed by 4231.89% in 2024.
  • Over the past 5 years, Pacific Health Care Organization's Cash & Equivalents (Quarter) stood at $10.1 million in 2021, then tumbled by 79.81% to $2.0 million in 2022, then grew by 22.47% to $2.5 million in 2023, then fell by 16.98% to $2.1 million in 2024, then increased by 5.23% to $2.2 million in 2025.
  • Its Cash & Equivalents was $2.2 million in Q3 2025, compared to $2.2 million in Q2 2025 and $2.4 million in Q1 2025.